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risk factor to ACL (p = 0.003; OR = 5.5; 95%; CI = 1.75—17.29).
With these results, we can conclude that ACL in Ilhéus is
not urban, since no typical vector species were found, and
the human cases were associated to the habit of going
to the rural area. Additionally, the case proﬁles, adult
males, showed that the subjects exposed demonstrate non-
compatible characteristics with a wider-ranging exposure,
as should be expected to happen if the illness transmis-
sion cycle took place in Ilhéus urban area. We also note
the importance of maintaining a strict registry of human
cases, with maximum rigidity, to guarantee speciﬁc diagnos-
tic for ACL, making possible epidemiological analysis more
trustworthy.
doi:10.1016/j.ijid.2008.05.1046
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Background: Antimicrobial resistance in enteric bacteria
is increasing worldwide. Little data is available on epidemi-
ology and the antimicrobial susceptibility pattern of enteric
pathogens in Shahrekord city of Iran.
Method: A 2-year prospective surveillance study was
performed on bacterial pathogens isolated from stool speci-
mens from community acquired gastroenteritis submitted to
Kashani Hospital in Shahrekord. The organisms were identi-
ﬁed using conventional laboratory methods. Antimicrobial
susceptibility tests for Salmonella spp and Shigella were
performed.
Results: There were 275 cases of bacterial gastroen-
teritis. Salmonella spp accounted for 42.1%, Shigella spp
33.1%, Campylobacter 24%. Resistance to ciproﬂoxacin was
uncommon in Salmonella spp (1.8%) and not detected in
Shigella spp. However ciproﬂoxacine resistance was high
in Campylobacter (50%). Cotrimoxazole resistance was high
in Shigella spp with a highest rate in S. Sonnei(92%). In
Salmonella spp cotrimoxazole resistance was 6.3%. Ery-
thromycine resistance in Campylobacter was uncommon.
The pattern of infection and resistance rate were similar
for adults and children.
Conclusion: The pattern of infection and antimicrobial
resistance in bacterial enteric pathogens in Iran has fea-
tures in common with both the developing and developed
world. Cotrimoxazole should not be used as empirical ther-
apy for dysentery. Quinolones should be used with caution
as empirical therapy for gastroenteritis because of the high
incidence of ciproﬂoxacin resistance in Campylobacter. Ery-
thromycin remains the agent of choice for Campylobacter
infection.
doi:10.1016/j.ijid.2008.05.1047
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Objectives: Bacterial infections are a serious health prob-
lem worldwide. We compared the efﬁcacy and safety of
gatiﬂoxacin, a new 8-methoxy ﬂuoroquinolone, with that of
levoﬂoxacin in the treatment of bacterial infections.
Methods: A randomized controlled multicentre clinical
trial was conducted, with levoﬂoxacin serving as the con-
trol drug. A total of 506 patients were enrolled in the study,
254 in the gatiﬂoxacin group and the other 252 in the lev-
oﬂoxacin group.
Results: The cure rates of gatiﬂoxacin and levoﬂoxacin
were 84.46% and 82.73%, and the overall efﬁcacy rates
were 96.41% and 95.58% respectively. The bacterial clear-
ance rates were 95.52% in gatiﬂoxacin group vs 93.69%
in levoﬂoxacin group. The adverse drug reaction rates
of gatiﬂoxacin and levoﬂoxacin were 10.63% and 10.71%
respectively. There was no statistically signiﬁcant dif-
ference between the two groups. The results of in
vitro activities of gatiﬂoxacin and other 4 antibacterial
agents showed that gatiﬂoxacin had good activities against
Staphylococcus spp. and was more potent than those of lev-
oﬂoxacin, sparﬂoxacin, ciproﬂoxacin and cefotaxime. The
activities of gatiﬂoxacin against Streptococcus spp. were
generally higher than those of levoﬂoxacin, sparﬂoxacin,
ciproﬂoxacin, and similar to those of cefotaxime. The activ-
ities of gatiﬂoxacin against Gram-negative organisms were
similar to or better than the other antibacterial agents.
Conclusion: Gatiﬂoxacin is an effective and on the basis
of this trial, a safe broad-spectrum antibacterial agent for
the treatment of bacterial infections.
doi:10.1016/j.ijid.2008.05.1048
